These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31394034)

  • 21. Synaptic Vesicle Glycoprotein 2A Ligands in the Treatment of Epilepsy and Beyond.
    Löscher W; Gillard M; Sands ZA; Kaminski RM; Klitgaard H
    CNS Drugs; 2016 Nov; 30(11):1055-1077. PubMed ID: 27752944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Presynaptic targeting of botulinum neurotoxin type A requires a tripartite PSG-Syt1-SV2 plasma membrane nanocluster for synaptic vesicle entry.
    Joensuu M; Syed P; Saber SH; Lanoue V; Wallis TP; Rae J; Blum A; Gormal RS; Small C; Sanders S; Jiang A; Mahrhold S; Krez N; Cousin MA; Cooper-White R; Cooper-White JJ; Collins BM; Parton RG; Balistreri G; Rummel A; Meunier FA
    EMBO J; 2023 Jul; 42(13):e112095. PubMed ID: 37226896
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cotrafficking of SV2 and synaptotagmin at the synapse.
    Yao J; Nowack A; Kensel-Hammes P; Gardner RG; Bajjalieh SM
    J Neurosci; 2010 Apr; 30(16):5569-78. PubMed ID: 20410110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Levetiracetam reverses synaptic deficits produced by overexpression of SV2A.
    Nowack A; Malarkey EB; Yao J; Bleckert A; Hill J; Bajjalieh SM
    PLoS One; 2011; 6(12):e29560. PubMed ID: 22220214
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synaptic vesicle glycoprotein 2C (SV2C) modulates dopamine release and is disrupted in Parkinson disease.
    Dunn AR; Stout KA; Ozawa M; Lohr KM; Hoffman CA; Bernstein AI; Li Y; Wang M; Sgobio C; Sastry N; Cai H; Caudle WM; Miller GW
    Proc Natl Acad Sci U S A; 2017 Mar; 114(11):E2253-E2262. PubMed ID: 28246328
    [TBL] [Abstract][Full Text] [Related]  

  • 26. SV2 renders primed synaptic vesicles competent for Ca2+ -induced exocytosis.
    Chang WP; Südhof TC
    J Neurosci; 2009 Jan; 29(4):883-97. PubMed ID: 19176798
    [TBL] [Abstract][Full Text] [Related]  

  • 27. SV2 regulates neurotransmitter release via multiple mechanisms.
    Nowack A; Yao J; Custer KL; Bajjalieh SM
    Am J Physiol Cell Physiol; 2010 Nov; 299(5):C960-7. PubMed ID: 20702688
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SV2A and SV2C contain a unique synaptotagmin-binding site.
    Schivell AE; Mochida S; Kensel-Hammes P; Custer KL; Bajjalieh SM
    Mol Cell Neurosci; 2005 May; 29(1):56-64. PubMed ID: 15866046
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Double receptor anchorage of botulinum neurotoxins accounts for their exquisite neurospecificity.
    Rummel A
    Curr Top Microbiol Immunol; 2013; 364():61-90. PubMed ID: 23239349
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluating the In Vivo Specificity of [
    Serrano ME; Becker G; Bahri MA; Seret A; Mestdagh N; Mercier J; Mievis F; Giacomelli F; Lemaire C; Salmon E; Luxen A; Plenevaux A
    Molecules; 2019 May; 24(9):. PubMed ID: 31052478
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Altered balance between excitatory and inhibitory inputs onto CA1 pyramidal neurons from SV2A-deficient but not SV2B-deficient mice.
    Venkatesan K; Alix P; Marquet A; Doupagne M; Niespodziany I; Rogister B; Seutin V
    J Neurosci Res; 2012 Dec; 90(12):2317-27. PubMed ID: 22847229
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Conservation of the amino acid sequence of SV2, a transmembrane transporter in synaptic vesicles and endocrine cells.
    Bindra PS; Knowles R; Buckley KM
    Gene; 1993 Dec; 137(2):299-302. PubMed ID: 8299963
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Botulinum Neurotoxin Serotype A Recognizes Its Protein Receptor SV2 by a Different Mechanism than Botulinum Neurotoxin B Synaptotagmin.
    Weisemann J; Stern D; Mahrhold S; Dorner BG; Rummel A
    Toxins (Basel); 2016 May; 8(5):. PubMed ID: 27196927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Synaptic vesicle protein 2 enhances release probability at quiescent synapses.
    Custer KL; Austin NS; Sullivan JM; Bajjalieh SM
    J Neurosci; 2006 Jan; 26(4):1303-13. PubMed ID: 16436618
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves.
    Mahrhold S; Rummel A; Bigalke H; Davletov B; Binz T
    FEBS Lett; 2006 Apr; 580(8):2011-4. PubMed ID: 16545378
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of SV2 isoforms during rodent brain development.
    Crèvecœur J; Foerch P; Doupagne M; Thielen C; Vandenplas C; Moonen G; Deprez M; Rogister B
    BMC Neurosci; 2013 Aug; 14():87. PubMed ID: 23937191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Loss of the SV2-like protein SVOP produces no apparent deficits in laboratory mice.
    Yao J; de la Iglesia HO; Bajjalieh SM
    PLoS One; 2013; 8(7):e68215. PubMed ID: 23894296
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological Profile of the Novel Antiepileptic Drug Candidate Padsevonil: Interactions with Synaptic Vesicle 2 Proteins and the GABA
    Wood M; Daniels V; Provins L; Wolff C; Kaminski RM; Gillard M
    J Pharmacol Exp Ther; 2020 Jan; 372(1):1-10. PubMed ID: 31619465
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The synaptic vesicle protein SV2 is complexed with an alpha5-containing laminin on the nerve terminal surface.
    Son YJ; Scranton TW; Sunderland WJ; Baek SJ; Miner JH; Sanes JR; Carlson SS
    J Biol Chem; 2000 Jan; 275(1):451-60. PubMed ID: 10617638
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Distribution of SV2C mRNA and protein expression in the mouse brain with a particular emphasis on the basal ganglia system.
    Dardou D; Dassesse D; Cuvelier L; Deprez T; De Ryck M; Schiffmann SN
    Brain Res; 2011 Jan; 1367():130-45. PubMed ID: 20869353
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.